338 related articles for article (PubMed ID: 24659969)
1. Labile iron in cells and body fluids: physiology, pathology, and pharmacology.
Cabantchik ZI
Front Pharmacol; 2014; 5():45. PubMed ID: 24659969
[TBL] [Abstract][Full Text] [Related]
2. Iron and oxidative stress in cardiomyopathy in thalassemia.
Berdoukas V; Coates TD; Cabantchik ZI
Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
[TBL] [Abstract][Full Text] [Related]
3. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.
Glickstein H; El RB; Link G; Breuer W; Konijn AM; Hershko C; Nick H; Cabantchik ZI
Blood; 2006 Nov; 108(9):3195-203. PubMed ID: 16835377
[TBL] [Abstract][Full Text] [Related]
4. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.
Espósito BP; Breuer W; Slotki I; Cabantchik ZI
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():42-9. PubMed ID: 11886431
[TBL] [Abstract][Full Text] [Related]
5. Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes.
Gu S; Xv Y; Fei C; Xiao C; Guo J; Zhao Y; Xv F; Li X; Chang C
Hematology; 2017 Jan; 22(1):9-15. PubMed ID: 27684730
[TBL] [Abstract][Full Text] [Related]
6. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.
Pootrakul P; Breuer W; Sametband M; Sirankapracha P; Hershko C; Cabantchik ZI
Blood; 2004 Sep; 104(5):1504-10. PubMed ID: 15155464
[TBL] [Abstract][Full Text] [Related]
7. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
[TBL] [Abstract][Full Text] [Related]
8. Labile plasma iron in iron overload: redox activity and susceptibility to chelation.
Esposito BP; Breuer W; Sirankapracha P; Pootrakul P; Hershko C; Cabantchik ZI
Blood; 2003 Oct; 102(7):2670-7. PubMed ID: 12805056
[TBL] [Abstract][Full Text] [Related]
9. LPI-labile plasma iron in iron overload.
Cabantchik ZI; Breuer W; Zanninelli G; Cianciulli P
Best Pract Res Clin Haematol; 2005 Jun; 18(2):277-87. PubMed ID: 15737890
[TBL] [Abstract][Full Text] [Related]
10. Utility of Labile Plasma Iron Assay in Thalassemia Major Patients.
Tripathi P; Pati HP; Mahapatra M; Tyagi S; Ahuja A; Saxena R
Indian J Hematol Blood Transfus; 2019 Apr; 35(2):272-277. PubMed ID: 30988563
[TBL] [Abstract][Full Text] [Related]
11. Labile plasma iron as an indicator of patient adherence to iron chelation treatment.
Steinberg-Shemer O; Yacobovich J; Cohen M; Cabantchik IZ; Tamary H
Blood Cells Mol Dis; 2018 Jul; 71():1-4. PubMed ID: 29395830
[TBL] [Abstract][Full Text] [Related]
12. Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation.
Bnaya A; Shavit L; Malyszko JS; Malyszko J; Slotki I
Ther Apher Dial; 2020 Aug; 24(4):416-422. PubMed ID: 31762187
[TBL] [Abstract][Full Text] [Related]
13. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation.
Naoum FA; Espósito BP; Ruiz LP; Ruiz MA; Tanaka PY; Sobreira JT; Cançado RD; de Barros JC
Acta Haematol; 2014; 131(4):222-6. PubMed ID: 24335268
[TBL] [Abstract][Full Text] [Related]
14. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.
Zanninelli G; Breuer W; Cabantchik ZI
Br J Haematol; 2009 Dec; 147(5):744-51. PubMed ID: 19764989
[TBL] [Abstract][Full Text] [Related]
15. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
[TBL] [Abstract][Full Text] [Related]
16. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Porter JB; El-Alfy M; Viprakasit V; Giraudier S; Chan LL; Lai Y; El-Ali A; Han J; Cappellini MD
Eur J Haematol; 2016 Jan; 96(1):19-26. PubMed ID: 25691036
[TBL] [Abstract][Full Text] [Related]
17. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.
Garbowski MW; Evans P; Vlachodimitropoulou E; Hider R; Porter JB
Haematologica; 2017 Oct; 102(10):1640-1649. PubMed ID: 28642302
[TBL] [Abstract][Full Text] [Related]
18. Rhinoceros serum labile plasma iron and associated redox potential: interspecific variation, sex bias and iron overload disorder disconnect.
Roth TL; Philpott M; Wojtusik J
Conserv Physiol; 2022; 10(1):coac025. PubMed ID: 37155459
[TBL] [Abstract][Full Text] [Related]
19. Redox active plasma iron in C282Y/C282Y hemochromatosis.
Le Lan C; Loréal O; Cohen T; Ropert M; Glickstein H; Lainé F; Pouchard M; Deugnier Y; Le Treut A; Breuer W; Cabantchik ZI; Brissot P
Blood; 2005 Jun; 105(11):4527-31. PubMed ID: 15671444
[TBL] [Abstract][Full Text] [Related]
20. Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants?
Rachmilewitz EA; Weizer-Stern O; Adamsky K; Amariglio N; Rechavi G; Breda L; Rivella S; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():118-23. PubMed ID: 16339657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
